Breast Cancer ASCO 2024 Highlights

Erika P. Hamilton, MD, and the Oncology Brothers presenting slides

EP. 1: RxPONDER: Use of AMH Levels in Premenopausal Women

ByRahul Gosain, MD,Rohit Gosain, MD,Erika P. Hamilton, MD

June 17th 2024

Following ASCO 2024, Erika P. Hamilton, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent updates from the RxPONDER trial investigating the use of AMH levels in premenopausal women.

EP. 2: Recent Updates from the postMONARCH Study

ByRahul Gosain, MD,Rohit Gosain, MD,Erika P. Hamilton, MD

June 17th 2024

The Oncology Brothers and Erika P. Hamilton, MD, discuss the postMONARCH study investigating fulvestrant alone vs fulvestrant plus abemaciclib.

EP. 3: INAVO120: Inavolisib Combination Therapy in PIK3CA-Mutated Breast Cancer

ByRahul Gosain, MD,Rohit Gosain, MD,Erika P. Hamilton, MD

June 17th 2024

Medical oncologists discuss the INAVO120 study, which is evaluating inavolisib combination therapy in patients with PIK3CA-mutated breast cancer.

EP. 4: Key Updates from DESTINY-Breast06

ByRahul Gosain, MD,Rohit Gosain, MD,Erika P. Hamilton, MD

June 17th 2024

Erika P. Hamilton, MD, and the Oncology Brothers review exciting data from DESTINY-Breast06 and discuss its impact on the evolving treatment landscape.

EP. 5: Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer

ByRahul Gosain, MD,Rohit Gosain, MD,Erika P. Hamilton, MD

June 17th 2024

Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.